

DOJOLVI (triheptanoin, oral)

Diagnosis Considered for Coverage:

- Long-chain fatty acid oxidation disorders (LC-FAODs)

Coverage Criteria:

For diagnosis listed above:

- Confirmation of LC-FAOD by genetic analysis, **and**
- Dose does not exceed FDA label maximum based upon weight and daily caloric intake.

Coverage Duration: one year

Effective Date: 11/30/2022